Catalyst

Slingshot members are tracking this event:

Alnylam (ALNY) Initiates APOLLO-B Phase 3 Study of Patisiran for the Treatment of Transthyretin Amyloidosis with Cardiomyopathy

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
ALNY

100%

Additional Information

Additional Relevant Details The primary endpoint is the change from baseline in the 6-minute walk test (6-MWT) at 12 months. Secondary endpoints will evaluate the efficacy of patisiran on quality of life using the Kansas City Cardiomyopathy Questionnaire Overall Summary, and composite endpoints of mortality and hospitalization.
http://investors.aln...
Slingshot Insights Explained
Catalyst Date
Occurred on:
Sep 16, 2019
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Apollo-b, Phase 3 Study, Patisiran, Transthyretin-mediated Amyloidosis, Cardiomyopathy